key: cord-0907328-zbnxrht7
authors: Cao, Jiasheng; Cai, Xiujun; Chen, Mingyu
title: Liver Injury in COVID-19: Caution and Management
date: 2020-07-14
journal: Liver Cancer
DOI: 10.1159/000508696
sha: 02461f8f8069cb68a7ab953d6f7d745870dc9c8b
doc_id: 907328
cord_uid: zbnxrht7

nan

Dear Editor, COVID-19 is an emerging infectious disease of SARS-CoV-2 origin that has become a global threat to human health, and the number of confirmed cases has exceeded 3,500,000 worldwide as of May 4, 2020. Previous studies almost focused on lung injury of COVID-19, while few articles have taken liver involvement into consideration, which ranged from 14.8 to 53% [1] .

Liver impairment is partly due to drug hepatotoxicity. Currently, medicines prescribed to treat COVID-19 include oseltamivir, ritonavir/lopinavir, ribavirin, and hydroxychloroquine sulfate, or chloroquine phosphate, which are metabolized in the liver and would produce hepatotoxicity, and the inducible liver injury can impair metabolism and excretion of the medications in turn. The postmortem biopsies of a COVID-19 patient showed mild lobular and portal activity, and moderate microvascular steatosis, which indicated that liver injury was SARS-CoV-2 infection-related or drug-related [2] . Therefore, clinicians should concentrate on liver injury and monitoring liver function in COVID-19 patients.

Liver injury in patients comorbid with chronic liver diseases and COVID-19 should be evaluated due to the global disease burden of chronic liver diseases, including chronic viral hepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver cancer, and so on. Although the interaction between COVID-19 and existing chronic liver diseases has not been studied, immune dysfunction is exactly a common feature in those patients and might be associated with disease severity and mortality. Moreover, considering the immunocompromised status, intensive surveillance and individually tailored therapy are appropriate for the above patients.

Notably, recipients of liver transplantation may have high risks of being infected with COVID-19 by hospital exposure during the outbreak [3] . Recipients may have higher potential to develop severe immune suppression and postoperative infection, which increase the rate of multisystem organ damage or death. There exists a contradiction that excessive immunosuppression leads to severe infections, while insufficient immunosuppression causes graft loss due to rejection reaction. A case report by Qin et al. [4] showed that a recipient had an

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient

We thank Jiliang Shen and Xu Feng for their efforts spent in checking the grammar errors in the manuscript.

The authors have no conflicts of interest to disclose.

The authors received no funding support for this study.

J.C. and X.C. designed and wrote the manuscript. M.C. supervised the study and revised the manuscript. All authors read and approved the final manuscript.